Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cellular Oncology

Open Access 26-04-2024 | Melanoma | Research

Targeting Dectin-1 and or VISTA enhances anti-tumor immunity in melanoma but not colorectal cancer model

Authors: Siavash Mashhouri, Amirhossein Rahmati, Ako Azimi, Roy A. Fava, Ismail Hassan Ismail, John Walker, Shokrollah Elahi

Published in: Cellular Oncology

Login to get access

Abstract

Purpose

Acquired resistance to immune checkpoint blockers (ICBs) is a major barrier in cancer treatment, emphasizing the need for innovative strategies. Dectin-1 (gene Clec7a) is a C-type lectin receptor best known for its ability to recognize β-glucan-rich structures in fungal cell walls. While Dectin-1 is expressed in myeloid cells and tumor cells, its significance in cancer remains the subject of controversy.

Methods

Using Celc7a-/- mice and curdlan administration to stimulate Dectin-1 signaling, we explored its impact. VISTA KO mice were employed to assess VISTA’s role, and bulk RNAseq analyzed curdlan effects on neutrophils.

Results

Our findings reveal myeloid cells as primary Dectin-1 expressing cells in the tumor microenvironment (TME), displaying an activated phenotype. Strong Dectin-1 co-expression/co-localization with VISTA and PD-L1 in TME myeloid cells was observed. While Dectin-1 deletion lacked protective effects, curdlan stimulation significantly curtailed B16-F10 tumor progression. RNAseq and pathway analyses supported curdlan’s role in triggering a cascade of events leading to increased production of pro-inflammatory mediators, potentially resulting in the recruitment and activation of immune cells. Moreover, we identified a heterogeneous subset of Dectin-1+ effector T cells in the TME. Similar to mice, human myeloid cells are the prominent cells expressing Dectin-1 in cancer patients.

Conclusion

Our study proposes Dectin-1 as a potential adjunctive target with ICBs, orchestrating a comprehensive engagement of innate and adaptive immune responses in melanoma. This innovative approach holds promise for overcoming acquired resistance to ICBs in cancer treatment, offering avenues for further exploration and development.
Appendix
Available only for authorised users
Literature
1.
2.
3.
F. Veglia, E. Sanseviero, D.I. Gabrilovich, Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol. 21(8), 485–498 (2021)PubMedPubMedCentralCrossRef
4.
Y. Yang, C. Li, T. Liu, X. Dai, A.V. Bazhin, Myeloid-derived suppressor cells in tumors: From mechanisms to antigen specificity and microenvironmental regulation. Front. Immunol. 11, 1371 (2020)PubMedPubMedCentralCrossRef
5.
6.
Y. Lin, J. Xu, H. Lan, Tumor-associated macrophages in tumor metastasis: Biological roles and clinical therapeutic applications. J. Hematol. Oncol. 12(1), 76 (2019)PubMedPubMedCentralCrossRef
7.
Y.-C. Chuang, J.-C. Tseng, L.-R. Huang, C.-M. Huang, C.-Y.F. Huang, T.-H. Chuang, Adjuvant effect of toll-like receptor 9 activation on cancer immunotherapy using checkpoint blockade. Front. Immunol. 11, 1075 (2020)PubMedPubMedCentralCrossRef
8.
9.
T. Shekarian, S. Valsesia-Wittmann, J. Brody, M.C. Michallet, S. Depil, C. Caux, et al., Pattern recognition receptors: Immune targets to enhance cancer immunotherapy. Ann. Oncol. 28(8), 1756–1766 (2017)PubMedCrossRef
10.
G.P. Amarante-Mendes, S. Adjemian, L.M. Branco, L.C. Zanetti, R. Weinlich, K.R. Bortoluci, Pattern recognition receptors and the host cell death molecular machinery. Front. Immunol. 9, 2379 (2018)PubMedPubMedCentralCrossRef
11.
12.
B. Huang, J. Zhao, J.C. Unkeless, Z.H. Feng, H. Xiong, TLR signaling by tumor and immune cells: a double-edged sword. Oncogene. 27(2), 218–224 (2008)PubMedCrossRef
13.
Z. Urban-Wojciuk, M.M. Khan, B.L. Oyler, R. Fåhraeus, N. Marek-Trzonkowska, A. Nita-Lazar, et al., The role of TLRs in anti-cancer immunity and tumor rejection. Front. Immunol. 10, 2388 (2019)PubMedPubMedCentralCrossRef
14.
E. Chiffoleau, C-type lectin-like receptors as emerging orchestrators of sterile inflammation represent potential therapeutic targets. Front. Immunol. 9, 227 (2018)PubMedPubMedCentralCrossRef
15.
16.
F. Osorio, C. Reis E Sousa, Myeloid C-type lectin receptors in pathogen recognition and host defense. Immunity. 34(5), 651–664 (2011)PubMedCrossRef
17.
D. Daley, V.R. Mani, N. Mohan, N. Akkad, A. Ochi, D.W. Heindel, et al., Dectin 1 activation on macrophages by galectin 9 promotes pancreatic carcinoma and peritumoral immune tolerance. Nat. Med. 23(5), 556–567 (2017)PubMedPubMedCentralCrossRef
18.
R. Kiyotake, M. Oh-Hora, E. Ishikawa, T. Miyamoto, T. Ishibashi, S. Yamasaki, Human mincle binds to cholesterol crystals and triggers innate immune responses. J. Biol. Chem. 290(42), 25322–25332 (2015)PubMedPubMedCentralCrossRef
19.
S. Mayer, M.-K. Raulf, B. Lepenies, C-type lectins: Their network and roles in pathogen recognition and immunity. Histochem. Cell Biol. 147(2), 223–237 (2016)PubMedCrossRef
20.
21.
S.E.M. Heinsbroek, P.R. Taylor, M. Rosas, J.A. Willment, D.L. Williams, S. Gordon, et al., Expression of functionally different Dectin-1 isoforms by murine macrophages. J. Immunol. 176(9), 5513–5518 (2006)PubMedCrossRef
22.
J.A. Willment, A.S.J. Marshall, D.M. Reid, D.L. Williams, S.Y.C. Wong, S. Gordon, et al., The human?-glucan receptor is widely expressed and functionally equivalent to murine Dectin-1 on primary cells. Eur. J. Immunol. 35(5), 1539–1547 (2005)PubMedCrossRef
23.
24.
E.L. Adams, P.J. Rice, B. Graves, H.E. Ensley, H. Yu, G.D. Brown, et al., Differential high-affinity interaction of Dectin-1 with natural or synthetic glucans is dependent upon primary structure and is influenced by polymer chain length and side-chain branching. J. Pharmacol. Exp. Ther. 325(1), 115–123 (2008)PubMedCrossRef
25.
S. Chiba, H. Ikushima, H. Ueki, H. Yanai, Y. Kimura, S. Hangai, et al., Recognition of tumor cells by Dectin-1 orchestrates innate immune cells for anti-tumor responses. Elife 3, e04177–e (2014)PubMedPubMedCentralCrossRef
26.
M. Liu, F. Luo, C. Ding, S. Albeituni, X. Hu, Y. Ma, et al., Dectin-1 activation by a natural product β-glucan converts immunosuppressive macrophages into an M1-like phenotype. J. Immunol. 195(10), 5055–5065 (2015)PubMedCrossRef
27.
P. Allavena, M. Chieppa, G. Bianchi, G. Solinas, M. Fabbri, G. Laskarin, et al., Engagement of the mannose receptor by tumoral mucins activates an immune suppressive phenotype in human tumor-associated macrophages. Clin. Dev. Immunol. 2010, 547179 (2010)PubMedCrossRef
28.
K. Bode, F. Bujupi, C. Link, T. Hein, S. Zimmermann, D. Peiris, et al., Dectin-1 binding to annexins on apoptotic cells induces peripheral immune tolerance via NADPH oxidase-2. Cell Rep. 29(13), 4435–46.e9 (2019)PubMedCrossRef
29.
S. Shahbaz, N. Bozorgmehr, P. Koleva, A. Namdar, J. Jovel, R.A. Fava, et al., CD71+VISTA+ erythroid cells promote the development and function of regulatory T cells through TGF-beta. PLoS Biol. 16(12), e2006649 (2018)PubMedPubMedCentralCrossRef
30.
N. Bozorgmehr, I. Okoye, S. Mashhouri, J. Lu, P. Koleva, J. Walker, et al., CD71(+) erythroid cells suppress T-cell effector functions and predict immunotherapy outcomes in patients with virus-associated solid tumors. J. Immunother. Cancer 11(5) (2023)
31.
N. Bozorgmehr, I. Okoye, O. Oyegbami, L. Xu, A. Fontaine, N. Cox-Kennett, et al., Expanded antigen-experienced CD160(+)CD8(+)effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia. J. Immunother. Cancer 9(4) (2021)
32.
S.R. Rosenbaum, M. Knecht, M. Mollaee, Z. Zhong, D.A. Erkes, P.A. McCue, et al., FOXD3 regulates VISTA expression in melanoma. Cell Rep. 30(2), 510–24.e6 (2020)PubMedPubMedCentralCrossRef
33.
S. Mashhouri, P. Koleva, M. Huynh, I. Okoye, S. Shahbaz, S. Elahi, Sex matters: Physiological abundance of immuno-regulatory CD71+ erythroid cells impair immunity in females. Front. Immunol. 12, 705197 (2021)PubMedPubMedCentralCrossRef
34.
M. Motamedi, S. Shahbaz, L. Fu, G. Dunsmore, L. Xu, R. Harrington, et al., Galectin-9 expression defines a subpopulation of NK cells with impaired cytotoxic effector molecules but enhanced IFN-gamma production, dichotomous to TIGIT, in HIV-1 infection. Immunohorizons 3(11), 531–546 (2019)PubMedCrossRef
35.
I. Okoye, L. Xu, M. Motamedi, P. Parashar, J.W. Walker, S. Elahi, Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors. J. Immuno. Ther. Cancer 8(2), e001849 (2020)CrossRef
36.
S. Shahbaz, J. Jovel, S. Elahi, Differential transcriptional and functional properties of regulatory T cells in HIV-infected individuals on antiretroviral therapy and long-term non-progressors. Clin. Transl. Immunol. 10(5), e1289 (2021)CrossRef
37.
S. Shahbaz, I. Okoye, G. Blevins, S. Elahi, Elevated ATP via enhanced miRNA-30b, 30c, and 30e downregulates the expression of CD73 in CD8+ T cells of HIV-infected individuals. PLoS Pathog. 18(3), e1010378 (2022)PubMedPubMedCentralCrossRef
38.
G. Dunsmore, N. Bozorgmehr, C. Delyea, P. Koleva, A. Namdar, S. Elahi, Erythroid suppressor cells compromise neonatal immune response against bordetella pertussis. J. Iimmunol. 199(6), 2081–2095 (2017)CrossRef
39.
N.L. Bray, H. Pimentel, P. Melsted, L. Pachter, Near-optimal probabilistic RNA-seq quantification. Nat. Biotechnol. 34(5), 525–527 (2016)PubMedCrossRef
40.
41.
Y. Zhao, X. Chu, J. Chen, Y. Wang, S. Gao, Y. Jiang, et al., Dectin-1-activated dendritic cells trigger potent antitumour immunity through the induction of Th9 cells. Nat. Commun. 7, 12368 (2016)PubMedPubMedCentralCrossRef
42.
Y. Xia, L. Liu, Q. Bai, J. Wang, W. Xi, Y. Qu, et al., Dectin-1 predicts adverse postoperative prognosis of patients with clear cell renal cell carcinoma. Sci. Rep. 6, 32657 (2016)PubMedPubMedCentralCrossRef
43.
P.R. Taylor, G.D. Brown, D.M. Reid, J.A. Willment, L. Martinez-Pomares, S. Gordon, et al., The β-glucan receptor, Dectin-1, is predominantly expressed on the surface of cells of the monocyte/macrophage and neutrophil lineages. J. Immunol. 169(7), 3876–3882 (2002)PubMedCrossRef
44.
W. Fan, X. Yang, F. Huang, X. Tong, L. Zhu, S. Wang, Identification of CD206 as a potential biomarker of cancer stem-like cells and therapeutic agent in liver cancer. Oncol. Lett. 18(3), 3218–3226 (2019)PubMedPubMedCentral
45.
F. Maibach, H. Sadozai, S.M. Seyed Jafari, R.E. Hunger, M. Schenk, Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma. Front. Immunol. 11, 2105 (2020)PubMedPubMedCentralCrossRef
46.
M. Peled, A. Onn, R.S. Herbst, Tumor-infiltrating lymphocytes—location for prognostic evaluation. Clin. Cancer Res. 25(5), 1449–1451 (2019)PubMedCrossRef
47.
E.K. Holl, V.N. Frazier, K. Landa, G.M. Beasley, E.S. Hwang, S.K. Nair, Examining peripheral and tumor cellular immunome in patients with cancer. Front. Immunol. 10, 1767 (2019)PubMedPubMedCentralCrossRef
48.
A. Schnell, C. Schmidl, W. Herr, P.J. Siska, The peripheral and intratumoral immune cell landscape in cancer patients: A proxy for tumor biology and a tool for outcome prediction. Biomedicines. 6(1), 25 (2018)PubMedPubMedCentralCrossRef
49.
B. Martin, K. Hirota, D.J. Cua, B. Stockinger, M. Veldhoen, Interleukin-17-producing γδ T cells selectively expand in response to pathogen products and environmental signals. Immunity 31(2), 321–330 (2009)PubMedCrossRef
50.
J. Liu, Y. Yuan, W. Chen, J. Putra, A.A. Suriawinata, A.D. Schenk, et al., Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses. Proc. Natl. Acad. Sci. U. S. A. 112(21), 6682–6687 (2015)PubMedPubMedCentralCrossRef
51.
L. Wang, I. Le Mercier, J. Putra, W. Chen, J. Liu, A.D. Schenk, et al., Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity. Proc. Natl. Acad. Sci. U. S. A. 111(41), 14846–14851 (2014)PubMedPubMedCentralCrossRef
52.
H.S. Kim, K.H. Park, H.K. Lee, J.S. Kim, Y.G. Kim, J.H. Lee, et al., Curdlan activates dendritic cells through dectin-1 and toll-like receptor 4 signaling. Int. Immunopharmacol. 39, 71–78 (2016)PubMedCrossRef
53.
W.Q. Li, J. Yan, Y. Yu, Geometrical reorganization of Dectin-1 and TLR2 on single phagosomes alters their synergistic immune signaling. Proc. Natl. Acad. Sci. U. S. A. 116(50), 25106–25114 (2019)PubMedPubMedCentralCrossRef
54.
M.E. Deerhake, K. Danzaki, M. Inoue, E.D. Cardakli, T. Nonaka, N. Aggarwal, et al., Dectin-1 limits autoimmune neuroinflammation and promotes myeloid cell-astrocyte crosstalk via Card9-independent expression of Oncostatin M. Immunity 54(3), 484–98 e8 (2021)PubMedPubMedCentralCrossRef
55.
T. Liang, J.R. Chen, G.Y. Xu, Z.D. Zhang, J. Xue, H.P. Zeng, et al., STAT1 and CXCL10 involve in M1 macrophage polarization that may affect osteolysis and bone remodeling in extrapulmonary tuberculosis. Gene 809 (2022)
56.
M. Rapp, M.W.M. Wintergerst, W.G. Kunz, V.K. Vetter, M.M.L. Knott, D. Lisowski, et al., CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes. J. Exp. Med. 216(5), 1170–1181 (2019)PubMedPubMedCentralCrossRef
57.
A. Garcia-Diaz, D.S. Shin, B.H. Moreno, J. Saco, H. Escuin-Ordinas, G.A. Rodriguez, et al., Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 19(6), 1189–1201 (2017)PubMedPubMedCentralCrossRef
58.
P.J. Murray, J.E. Allen, S.K. Biswas, E.A. Fisher, D.W. Gilroy, S. Goerdt, et al., Macrophage activation and polarization: Nomenclature and experimental guidelines. Immunity 41(1), 14–20 (2014)PubMedPubMedCentralCrossRef
59.
Y.L. Latour, A.P. Gobert, K.T. Wilson, The role of polyamines in the regulation of macrophage polarization and function. Amino Acids. 52(2), 151–160 (2020)PubMedCrossRef
60.
C. Tang, H. Sun, M. Kadoki, W. Han, X. Ye, Y. Makusheva, et al., Blocking Dectin-1 prevents colorectal tumorigenesis by suppressing prostaglandin E2 production in myeloid-derived suppressor cells and enhancing IL-22 binding protein expression. Nat. Commun. 14(1), 1493 (2023)PubMedPubMedCentralCrossRef
61.
S. Shalapour, J. Font-Burgada, G. Di Caro, Z. Zhong, E. Sanchez-Lopez, D. Dhar, et al., Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature 521(7550), 94–98 (2015)PubMedPubMedCentralCrossRef
62.
63.
N. Bozorgmehr, H. Syed, S. Mashhouri, J. Walker, S. Elahi, Transcriptomic profiling of peripheral blood cells in HPV-associated carcinoma patients receiving combined valproic acid and avelumab. Mol. Oncol. (2023)
64.
L. Corrales, V. Matson, B. Flood, S. Spranger, T.F. Gajewski, Innate immune signaling and regulation in cancer immunotherapy. Cell Res. 27(1), 96–108 (2017)PubMedCrossRef
65.
O. Demaria, S. Cornen, M. Daëron, Y. Morel, R. Medzhitov, E. Vivier, Harnessing innate immunity in cancer therapy. Nature. 574(7776), 45–56 (2019)PubMedCrossRef
66.
J.N. Kather, N. Halama, Harnessing the innate immune system and local immunological microenvironment to treat colorectal cancer. Br. J. Cancer. 120(9), 871–882 (2019)PubMedPubMedCentralCrossRef
67.
M.G. Lechner, S.S. Karimi, K. Barry-Holson, T.E. Angell, K.A. Murphy, C.H. Church, et al., Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J. Immunother. 36(9), 477–489 (2013)PubMedPubMedCentralCrossRef
68.
S.H. Albeituni, C. Ding, M. Liu, X. Hu, F. Luo, G. Kloecker, et al., Yeast-derived particulate β-glucan treatment subverts the suppression of myeloid-derived suppressor cells (MDSC) by inducing polymorphonuclear MDSC apoptosis and monocytic MDSC differentiation to APC in cancer. J. Immunol. 196(5), 2167–2180 (2016)PubMedCrossRef
69.
G.D. Brown, Dectin-1: A signalling non-TLR pattern-recognition receptor. Nat. Rev. Immunol. 6(1), 33–43 (2005)CrossRef
70.
J.A. Willment, -H.-H. Lin, D.M. Reid, P.R. Taylor, D.L. Williams, S.Y.C. Wong, et al., Dectin-1 expression and function are enhanced on alternatively activated and GM-CSF-treated macrophages and are negatively regulated by IL-10, dexamethasone, and lipopolysaccharide. J. Immunol. 171(11), 6297 (2003)CrossRef
71.
E. Beyranvand Nejad, T.C. van der Sluis, S. van Duikeren, H. Yagita, G.M. Janssen, P.A. van Veelen, et al., Tumor eradication by cisplatin is sustained by CD80/86-mediated costimulation of CD8+ T cells. Cancer Res. 76(20), 6017–6029 (2016)PubMedCrossRef
72.
O.A.W. Haabeth, T.R. Blake, C.J. McKinlay, A.A. Tveita, A. Sallets, R.M. Waymouth, et al., Local delivery of Ox40l, Cd80, and Cd86 mRNA kindles global anticancer immunity. Cancer Res. 79(7), 1624–1634 (2019)PubMedPubMedCentralCrossRef
73.
J.J. Miret, P. Kirschmeier, S. Koyama, M. Zhu, Y.Y. Li, Y. Naito, et al., Suppression of myeloid cell arginase activity leads to therapeutic response in a NSCLC mouse model by activating anti-tumor immunity. J. Immunother. Cancer 7(1), 32 (2019)PubMedPubMedCentralCrossRef
74.
75.
S. Elahi, J.M. Ertelt, J.M. Kinder, T.T. Jiang, X. Zhang, L. Xin, et al., Immunosuppressive CD71+ erythroid cells compromise neonatal host defence against infection. Nature 504(7478), 158–162 (2013)PubMedPubMedCentralCrossRef
76.
S. Elahi, S. Mashhouri, Immunological consequences of extramedullary erythropoiesis: Immunoregulatory functions of CD71(+) erythroid cells. Haematologica. 105(6), 1478–1483 (2020)PubMedPubMedCentralCrossRef
77.
78.
C. Bogdan, M. Röllinghoff, A. Diefenbach, Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity. Curr. Opin. Immunol. 12(1), 64–76 (2000)PubMedCrossRef
79.
Ö. Canli, A.M. Nicolas, J. Gupta, F. Finkelmeier, O. Goncharova, M. Pesic, et al., Myeloid cell-derived reactive oxygen species induce epithelial mutagenesis. Cancer Cell 32(6), 869–83.e5 (2017)PubMedCrossRef
80.
J.D. Lambeth, A.S. Neish, Nox enzymes and new thinking on reactive oxygen: A double-edged sword revisited. Ann. Rev. Pathol. Mech. Dis. 9(1), 119–145 (2014)CrossRef
81.
R. Coriat, W. Marut, M. Leconte, L.B. Ba, A. Vienne, C. Chéreau, et al., The organotelluride catalyst LAB027 prevents colon cancer growth in the mice. Cell Death Dis. 2(8), e191–e (2011)PubMedPubMedCentralCrossRef
82.
R.M. Brand, P. Wipf, A. Durham, M.W. Epperly, J.S. Greenberger, L.D. Falo Jr, Targeting mitochondrial oxidative stress to mitigate UV-induced skin damage. Front. Pharmacol. 9, 920 (2018)PubMedPubMedCentralCrossRef
83.
A.K.-W. Tse, Y.-J. Chen, F. X-q, T. Su, T. Li, H. Guo, et al., Sensitization of melanoma cells to alkylating agent-induced DNA damage and cell death via orchestrating oxidative stress and IKKβ inhibition. Redox Biol. 11, 562–576 (2017)PubMedPubMedCentralCrossRef
84.
H.-T. Wang, B. Choi, T. M-s, Melanocytes are deficient in repair of oxidative DNA damage and UV-induced photoproducts. Proc. Natl. Acad. Sci. U. S. A. 107(27), 12180–12185 (2010)PubMedPubMedCentralCrossRef
85.
I.S. Okoye, M. Houghton, L. Tyrrell, K. Barakat, S. Elahi, Coinhibitory receptor expression and immune checkpoint blockade: Maintaining a balance in CD8(+) T cell responses to chronic viral infections and cancer. Front. Immunol. 8, 1215 (2017)PubMedPubMedCentralCrossRef
86.
S. Elahi, W.L. Dinges, N. Lejarcegui, K.J. Laing, A.C. Collier, D.M. Koelle, et al., Protective HIV-specific CD8+ T cells evade Treg cell suppression. Nature Med. 17(8), 989–995 (2011)PubMedCrossRef
87.
S. Elahi, S. Shahbaz, S. Houston, Selective upregulation of CTLA-4 on CD8+ T cells restricted by HLA-B*35Px renders them to an exhausted phenotype in HIV-1 infection. PLoS Pathogens. 16(8), e1008696–e (2020)PubMedPubMedCentralCrossRef
88.
S. Shahbaz, G. Dunsmore, P. Koleva, L. Xu, S. Houston, S. Elahi, Galectin-9 and VISTA expression define terminally exhausted T cells in HIV-1 infection. J. Immunol. 204(9), 2474–2491 (2020)PubMedCrossRef
89.
S. Shahbaz, L. Xu, W. Sligl, M. Osman, N. Bozorgmehr, S. Mashhouri, et al., The quality of SARS-CoV-2–specific T cell functions differs in patients with mild/moderate versus severe disease, and T cells expressing coinhibitory receptors are highly activated. J. Immunol. 207(4), 1099–1111 (2021)PubMedCrossRef
90.
R. Yang, L. Sun, L. C-f, Y.-H. Wang, J. Yao, H. Li, et al., Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat. Commun. 12(1), 832 (2021)PubMedPubMedCentralCrossRef
91.
I. Le Mercier, W. Chen, J.L. Lines, M. Day, J. Li, P. Sergent, et al., VISTA regulates the development of protective antitumor immunity. Cancer Res. 74(7), 1933–1944 (2014)PubMedCrossRef
92.
N. Mehta, S. Maddineni, I.I. Mathews, R. Andres Parra Sperberg, P.-S. Huang, J.R. Cochran, Structure and functional binding epitope of V-domain Ig suppressor of T cell activation. Cell Rep. 28(10), 2509–16.e5 (2019)PubMedCrossRef
93.
94.
J. Deng, J. Li, A. Sarde, J.L. Lines, Y.-C. Lee, D.C. Qian, et al., Hypoxia-induced VISTA promotes the suppressive function of myeloid-derived suppressor cells in the tumor microenvironment. Cancer Immunol. Res. 7(7), 1079–1090 (2019)PubMedPubMedCentralCrossRef
95.
J.L. Lines, E. Pantazi, J. Mak, L.F. Sempere, L. Wang, S. O’Connell, et al., VISTA is an immune checkpoint molecule for human T cells. Cancer Res. 74(7), 1924–1932 (2014)PubMedPubMedCentralCrossRef
96.
L. Wu, -W.-W. Deng, C.-F. Huang, B. L-L, Y. G-T, L. Mao, et al., Expression of VISTA correlated with immunosuppression and synergized with CD8 to predict survival in human oral squamous cell carcinoma. Cancer Immunol. Immunother. 66(5), 627–636 (2017)PubMedCrossRef
97.
W. Xu, J. Dong, Y. Zheng, J. Zhou, Y. Yuan, H.M. Ta, et al., Immune-checkpoint protein VISTA regulates antitumor immunity by controlling myeloid cell-mediated inflammation and immunosuppression. Cancer Immunol. Res. 7(9), 1497–1510 (2019)PubMedPubMedCentralCrossRef
98.
H. Huang, G.R. Ostroff, C.K. Lee, S. Agarwal, S. Ram, P.A. Rice, et al., Relative contributions of dectin-1 and complement to immune responses to particulate β-glucans. J. Immunol. 189(1), 312–317 (2012)PubMedCrossRef
99.
X. Qiu, A.S.H. Chan, A.B. Jonas, T. Kangas, N.R. Ottoson, J.R. Graff, et al., Imprime PGG, a yeast β-glucan PAMP elicits a coordinated immune response in combination with anti-PD1 antibody. J. Immunol. 196(1_Supplement), 214.16 (2016)CrossRef
100.
M. Zhang, J.A. Kim, A.Y.-C. Huang, Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles. Front. Immunol. 9, 341 (2018)PubMedPubMedCentralCrossRef
101.
J.M. Zaretsky, A. Garcia-Diaz, D.S. Shin, H. Escuin-Ordinas, W. Hugo, S. Hu-Lieskovan, et al., Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375(9), 819–829 (2016)PubMedPubMedCentralCrossRef
102.
K.D. Moynihan, C.F. Opel, G.L. Szeto, A. Tzeng, E.F. Zhu, J.M. Engreitz, et al., Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat. Med. 22(12), 1402–1410 (2016)PubMedPubMedCentralCrossRef
Metadata
Title
Targeting Dectin-1 and or VISTA enhances anti-tumor immunity in melanoma but not colorectal cancer model
Authors
Siavash Mashhouri
Amirhossein Rahmati
Ako Azimi
Roy A. Fava
Ismail Hassan Ismail
John Walker
Shokrollah Elahi
Publication date
26-04-2024
Publisher
Springer Netherlands
Keywords
Melanoma
Melanoma
Published in
Cellular Oncology
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-024-00950-w
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits